Insiders At Medpace Holdings Sold US$525m In Stock, Alluding To Potential Weakness
Insiders At Medpace Holdings Sold US$525m In Stock, Alluding To Potential Weakness
In the last year, many Medpace Holdings, Inc. (NASDAQ:MEDP) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在過去的一年裏,許多Medpace Holdings, Inc.(納斯達克:MEDP)內部人士拋售了公司的大量股份,可能引起了股東的關注。在分析內部交易時,了解內部人士是在買入還是賣出通常更有價值,因爲後者傳遞了模棱兩可的信息。然而,如果有幾位內部人士在特定時期內拋售股票,股東們應該更深入地觀察。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
雖然我們永遠不會建議投資者僅基於公司董事已經做出的決策而做出決策,但同時我們認爲完全忽略內部交易是愚蠢的。
Medpace Holdings Insider Transactions Over The Last Year
過去一年來,Medpace Holdings 內部交易
Over the last year, we can see that the biggest insider sale was by the Chairman & CEO, August Troendle, for US$82m worth of shares, at about US$413 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$363. So it may not shed much light on insider confidence at current levels.
在過去一年中,我們可以看到董事長兼首席執行官August Troendle進行了最大規模的內部人士賣出,價值8200萬美元的股份,每股約413美元。一般來說,我們不喜歡看到內部人士拋售股票,但銷售價格越低,我們就越擔憂。值得一提的是,這次賣出的價格遠高於當前股價363美元。所以這並沒有對內部人士在當前水平上的信心提供太多線索。
In the last year Medpace Holdings insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在過去一年中,Medpace Holdings 內部人士沒有購買任何公司股票。您可以在下圖中看到過去一年內部交易(按公司和個人)的情況。如果您想準確了解誰以及何時以多少價格出售,請單擊下面的圖表!
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜歡購買內部人員正在購買而不是銷售的股票,那麼你可能會喜歡這份免費的公司列表。(提示:它們中的大部分都被忽視了。)
Does Medpace Holdings Boast High Insider Ownership?
medpace控股公司是否擁有高比例的內部人員所有權?
Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It's great to see that Medpace Holdings insiders own 18% of the company, worth about US$2.0b. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
許多投資者喜歡查看公司內部人員持有多少比例的股份。我們通常希望看到相當高比例的內部人員所有權。很高興看到medpace控股公司的內部人員擁有該公司18%的股份,價值約20億美元。大多數股東會很高興看到這種內部人員所有權,因爲這表明管理層的激勵與其他股東的利益保持良好一致。
What Might The Insider Transactions At Medpace Holdings Tell Us?
medpace控股公司的內部交易可能告訴我們什麼?
There haven't been any insider transactions in the last three months -- that doesn't mean much. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the Medpace Holdings insiders selling. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for Medpace Holdings.
在過去三個月內沒有內部交易--這並沒有太多意義。很高興看到較高比例的內部所有權,但回顧過去一年,我們並不認爲medpace控股公司內部人員的賣出行爲會讓人有信心。因此,您絕對應該查看這份免費報告,其中列出了對medpace控股公司的分析師預測。
But note: Medpace Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:medpace控股可能不是最好的股票買入選擇。因此,請看一下這份免費的股票列表,其中包含具有高roe和低債務的有趣公司。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。